Zacks Investment Research upgraded shares of Vistagen Therapeutics (NASDAQ:VTGN) from a hold rating to a buy rating in a research note issued to investors on Thursday. Zacks Investment Research currently has $1.50 price target on the stock.

According to Zacks, “VistaGen Therapeutics, Inc. is a biotechnology company. It is engaged in developing and commercializing product candidates for diseases and disorders involving the central nervous system. The company’s lead product candidate consists of AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of major depressive disorder. VistaGen Therapeutics, Inc. is headquartered in South San Francisco, California. “

Other equities research analysts have also issued research reports about the stock. Oppenheimer started coverage on shares of Vistagen Therapeutics in a report on Thursday, May 24th. They issued a buy rating and a $6.00 price target on the stock. Maxim Group set a $6.00 price target on shares of Vistagen Therapeutics and gave the stock a buy rating in a report on Tuesday, August 14th. Chardan Capital reissued a buy rating and issued a $22.00 price target on shares of Vistagen Therapeutics in a report on Friday, June 29th. Finally, UBS Group started coverage on shares of Vistagen Therapeutics in a report on Thursday, May 24th. They issued an outperform rating and a $6.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The company presently has an average rating of Buy and an average price target of $8.30.

Shares of VTGN stock traded down $0.02 on Thursday, hitting $1.47. 20,034 shares of the company’s stock traded hands, compared to its average volume of 131,565. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65. The firm has a market cap of $37.17 million, a P/E ratio of -1.32 and a beta of 0.14.

Vistagen Therapeutics (NASDAQ:VTGN) last released its earnings results on Tuesday, August 14th. The company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by ($0.06). equities analysts predict that Vistagen Therapeutics will post -0.75 earnings per share for the current fiscal year.

About Vistagen Therapeutics

VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.

Read More: Moving Average – How it Helps Investors in Stock Selection

Get a free copy of the Zacks research report on Vistagen Therapeutics (VTGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.